Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials

Author： Salam Amar M  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.13, Iss.6, 2004-06, pp. : 707-713

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lipid-lowering therapy in acute coronary syndromes

By  

Inpharma, Vol. 1, Iss. 1283, 2001-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US

By Rosen Virginia M.  

PharmacoEconomics, Vol. 28, Iss. 1, 2010-01 ,pp. : 47-60

Adis International

Access to resources Recommend Favorite

Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease

By Nieminen Tuomo   Käähöönen Mika   Viiri Leena E   Gröönroos Paula   Lehtimääki Terho  

Pharmacogenomics, Vol. 9, Iss. 10, 2008-10 ,pp. : 1475-1486

Future Medicine

Access to resources Recommend Favorite

Lipid-Lowering Treatment in Coronary Artery Disease: How Low Should Cholesterol Go?

By Jones P.H.  

Drugs, Vol. 59, Iss. 5, 2000-05 ,pp. : 1127-1135

Adis International

Access to resources Recommend Favorite

Lipid-lowering therapy in diabetes

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 342, 2001-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite